Teva Reports Third-Quarter 2026 Revenue of $4.4B, Net Income of $233M
Revenue fell 1.9% from $4.48B a year earlier, while net income declined 46.2% and diluted EPS fell 45.9% to $0.2.
Teva Pharmaceutical Industries reported third-quarter 2026 revenue of $4.4B, down 1.9% from $4.48B a year earlier. Net income declined 46.2% to $233M, while diluted EPS fell 45.9% to $0.2.Financial Highlights¹ Reported as “Net revenues”. ² Reported as “Net income (loss) attributable to Teva”. ³ Rep…